Herzuma

Herzuma

Herzuma® (CT-P6) is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018.

Herzuma® is a humanized monoclonal antibody that is designed to bind selectively to the extracellular domain of an antigen called human epidermal growth factor receptor 2 (HER2).
Herzuma® is indicated for the treatment of adult patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Herzuma®, biosimilar trastuzumab (approved by the EMA in 2018)

  • Indications :
    - Early breast cancer
    - Metastatic breast cancer
    - Metastatic gastric cancer
  • Protein Type :
    - Monoclonal antibody (mAb)
  • Mechanism of Action :
    - Trastuzumab prevents auto-activation of HER2 receptor, activates antibody-dependent cellular cytotoxicity, and promotes degradation of HER2.